Using the glucometrics website to benchmark ICU glucose control before and after the NICE-SUGAR study.

Prior to 2009, intensive glycemic control was the standard in main intensive care units (ICUs). Glucose targets have been recalibrated after publication of the NICE-SUGAR study in that year, followed by updated guidelines that endorsed more moderated control. We sought to determine if the prevalence of hyperglycemia in US ICUs had increased after the NICE-SUGAR study's results were reported.

Effects on post-prandial glucose and AGE precursors from two initial insulin strategies in patients with type 2 diabetes uncontrolled by oral agents.

Objective: Progressive β-cell dysfunction in Type 2 diabetes results in the need for insulin therapy in many patients. Yet the best regimen to prescribe to patients transitioning from oral anti-hyperglycemic drugs (OADs) is not clear. We sought to compare the effects of two standard initial insulin strategies (basal insulin alone versus premixed insulin) on post-prandial glucose metabolism and precursors of advanced glycation end-products in patients with type 2 diabetes suboptimally controlled on OADs.

Hospital management of hyperglycemia.

Purpose Of Review: With the growing prevalence of dysglycemia, the increased frequency of hospitalizations in diabetic patients, and the notable effects of acute stress on glucose metabolism, it is not surprising that hyperglycemia is frequently encountered in the inpatient setting. Hospital hyperglycemia is associated with increased morbidity and mortality, as well as increased length of stay and costs. Accordingly, there has been intense interest in the optimal management of glucose levels in hospitalized patients.

Diagnosis and management of pituitary adenomas.

Purpose Of Review: Pituitary adenomas are frequently encountered in practice either because of clinical symptoms or as incidental findings. These tumors may alter pituitary function and can therefore have a considerable impact on morbidity, mortality, and quality of life.

Recent Findings: The presentation is variable for each type of tumor, with microadenomas being either silent or manifesting with symptoms of hormonal excess.